Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 91, Issue 3, 2011, Pages

  Bell, P M ^a   Cuthbertson, J ^a   Patterson, S ^b   O'Harte, F P M ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

GLP 1; Nateglinide; Postprandial glycaemia

Indexed keywords

DECAPENTAPLEGIC PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PLACEBO;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; MALE; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; PHENYLALANINE; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 79952361076     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.11.033     Document Type: Article

References (11)

1. Whitelaw D.C., Clark P.M., Smith J.M., Natrass M. Effects of the new oral hypoglycaemic agent nateglinide in insulin secretion in type 2 diabetes. Diabet Med 2000, 17:225-229.
2. Keilson L., Mather S., Walter Y.H., Subramanian S., McLeod J.F. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes. J Clin Endocrinol Metab 2000, 85:1081-1086.
3. Duffy N.A., Green B.D., Irwin N., Gault V.A., McKillop A.M., O'Harte F.P.M., et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol 2007, 568:278-286.
4. McKillop A.M., Duffy N.A., Lindsay J.R., Green B.D., O'Harte F.P.M., Bell P.M., et al. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. Eur J Endocrinol 2009, 161:877-885.
5. Knop F., Vilsbøll T., Larsen S., Madsbad M., Holst J.T. No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. Diabetes Care 2003, 26:2581-2587.
6. Lindsay J.R., Duffy N.A., McKillop A.M., Ardill J., O'Harte F.P.M., Flatt P.R., et al. Inhibition of dipeptidyl peptidase IV (DPP-IV) activity by oral metformin in type 2 diabetes. Diabet Med 2005, 22:654-657.
7. McKillop A.M., Duffy N.A., Lindsay J.R., O'Harte F.P.M., Bell P.M., Flatt P.R. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008, 79:79-85.
8. Green B., Duffy N.A., Irwin N., Gault V.A., O'Harte F.P.M., Flatt P.R. Inhibition of dipeptidyl peptidase IV (DPPIV) activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (GLP-1). Eur J Pharmacol 2006, 547:192-199.
9. The Navigator Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362:1463-1476.
10. Horton E.S., Clinkingbeard C., Gatlin M., Foley J., Mallows S., Shen S. Nateglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000, 23:1660-1665.
11. Herman G.A., Stevens C., Van Dyck K., Bergman A., Yi B., De Smet M., et al. Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects. Clin Pharmacol Ther 2005, 78:675-688.